Literature DB >> 28389391

Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.

Marcus Maurer1, Andrea Schütz1, Karsten Weller1, Nicole Schoepke1, Adriane Peveling-Oberhag2, Petra Staubach2, Sabine Müller3, Thilo Jakob4, Martin Metz5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28389391     DOI： 10.1016/j.jaci.2017.01.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  13 in total

1.  Clinical impact of omalizumab in refractory chronic urticaria: One centre experience.

Authors:  Diana Deleanu; Irena Nedelea; Carina Petricau; Poliana Leru; Dinu Dumitrascu; Adriana Muntean
Journal:  Exp Ther Med       Date:  2019-10-24       Impact factor: 2.447

Review 2.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

3.  Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study.

Authors:  Simon F Thomsen; Ellen C Pritzier; Chris D Anderson; Siri Juvik; Nicolas V Baust; Rikke Dodge; Anna-Karin Dahlborn; Christian Vestergaard
Journal:  Acta Derm Venereol       Date:  2022-04-07       Impact factor: 3.875

Review 4.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

Review 5.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

Review 6.  Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic.

Authors:  Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-09       Impact factor: 4.806

Review 7.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

Review 8.  Chronic urticaria: a focus on pathogenesis.

Authors:  Riccardo Asero; Alberto Tedeschi; Angelo Valerio Marzano; Massimo Cugno
Journal:  F1000Res       Date:  2017-07-11

9.  Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.

Authors:  Eva Serrano-Candelas; Rubén Martínez-Aranguren; Olga Vega; Gabriel Gastaminza; Joan Bartra; Maria Teresa Audicana; Jorge M Núñez-Córdoba; Jaime Algorta; Antonio Valero; Margarita Martin; Marta Ferrer
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

10.  Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.

Authors:  M Maurer; K Houghton; C Costa; F Dabove; L F Ensina; A Giménez-Arnau; G Guillet; G N Konstantinou; M Labrador-Horrillo; H Lapeere; R Meshkova; E A Pastorello; M Velásquez-Lopera; L M Tamayo Quijano; C Vestergaard; N Chapman-Rothe
Journal:  World Allergy Organ J       Date:  2018-11-16       Impact factor: 4.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.